SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
Bank of New York Mellon Corp decreased its stake in Stryker Corporation (NYSE: SYK) by 10.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,548,516 shares of the medical technology company's stock after selling 403,885 shares during the
Advisors Preferred LLC acquired a new stake in shares of Stryker Corporation (NYSE: SYK) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,300 shares of the medical technology company's stock, valued at approximately $1,404,000. A number
B. Metzler seel. Sohn and Co. AG bought a new position in shares of Stryker Corporation (NYSE: SYK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 120,896 shares of the medical technology company's stock, valued at approximately $38,063,000. A number of
AlpenGlobal Capital LLC bought a new stake in Stryker Corporation (NYSE: SYK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,155 shares of the medical technology company's stock, valued at approximately $1,938,000. Stryker makes up about 1.2% of AlpenGlobal Capital LLC's
Advisors Capital Management LLC bought a new position in shares of Stryker Corporation (NYSE: SYK) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 89,485 shares of the medical technology company's stock, valued at approximately $28,173,000. Several other institutional investors
Shares of Stryker Corporation (NYSE: SYK - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-four research firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy
Stryker (SYK) rebounded in Q2 with 9% organic growth, restoring confidence after a weak Q1. Both MedSurg & Neurotech and Orthopaedics segments sharply accelerated, indicating Q1 weakness was temporary. Guidance was modestly adjusted, but demand remains strong and growth is broad-based across product lines.
BlackRock Inc. cut its position in Stryker Corporation (NYSE: SYK) by 0.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,414,742 shares of the medical technology company's stock after selling 187,307 shares during the quarter. BlackRock Inc. owned about
Argent Trust Co grew its stake in Stryker Corporation (NYSE: SYK) by 66.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,889 shares of the medical technology company's stock after purchasing an additional 6,339 shares during the quarter. Argent
